5. The Downfall

5. The Downfall

Up next

Introducing 'Burden of Proof: Luigi Mangione'

Today, we're sharing the first episode of our latest series from ABC Audio and 20/20, 'Burden of Proof: Luigi Mangione.' In episode one, the manhunt for the alleged shooter of UnitedHealthcare CEO Brian Thompson comes to an end at a McDonald's in Altoona, PA. To keep listening, f ...  Show more

Bonus: Sentenced

In a special bonus episode of "The Dropout: Elizabeth Holmes on Trial," we break down what happened during Holmes' sentencing hearing and what is next for the once-lauded Theranos founder. Learn more about your ad choices. Visit megaphone.fm/adchoices 

Recommended Episodes

Ep. 214: Blood Feud - The U.S. v. Elizabeth Holmes
Law360's Pro Say - News & Analysis on Law and the Legal Industry

The upcoming criminal trial of former Theranos CEO Elizabeth Holmes figures to center around one crucial question: Was the blood testing startup’s failure a case of misguided Silicon Valley over-ambition, or was it outright fraud? Law360’s Dorothy Atkins has been covering the The ...  Show more

Elizabeth Holmes: The downfall of a billion dollar startup
The Story

Elizabeth Holmes was once hailed as a visionary, and her company Theranos was set to revolutionise the world of medicine. But her success was a tale of hot air and hubris. Last week, Holmes was convicted of fraud and conspiracy. How was this silicon valley star brought down by a ...  Show more

The United States v. Elizabeth Holmes
The Daily

When Elizabeth Holmes founded Theranos, the blood testing start-up, she was held up as one of the next great tech innovators.

But her company collapsed, and she was accused of lying about how well Theranos’s technology worked. Now she is on trial on fraud charges.

...

  Show more

Holmes stretch: Theranos’s founder convicted
Economist Podcasts

Elizabeth Holmes has been found guilty of fraud. We ask what lessons her downfall holds for Theranos’s high-profile backers—and for a startup culture of hype before science. As Apple crosses a $3trn valuation we examine the motives for its stop-start forays into the competitiv ...

  Show more